anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE:To obtain the subject ameliorant, containing an isoxazolone derivative as an active ingredient, capable of activating mammalian nerve cells, promoting hypermnesia with low toxicity and effective against dysmnesia due to cerebral apoplexy, Alzherimer&#39;s diseases, head injuries, etc. CONSTITUTION:An ameliorant containing a compound expressed by formula I (R&lt;1&gt; is H or lower alkyl; R&lt;2&gt; is amino which may be protected; COR&lt;3&gt; is carboxyl which may be esterified; (n) is 0-3) as an active ingredient. In use, the aforementioned compound is mixed with a pharmaceutically acceptable carrier and used in a dosage form of tablet, pellet, injection, etc. Furthermore, the compound expressed by formula I which is the active ingredient is synthesized by reacting, e.g. a compound expressed by formula II (COOR&lt;4&gt; is esterified carboxyl group) with hydroxylamine and subjecting the resultant product to cyclizing reaction. The compound expressed by formula II is synthesized by using an epsilon-carboxyl-alpha-amino acid derivative and carbonyldiimidazole as starting raw materials.
PROBLEM TO BE SOLVED: To obtain a liquid enteral nutrition composition having a preventing and treating effect on life ctyle-related diseases, such as ameliorating activities on serum lipid, antiobestic effect, etc., even by tube feeding nutrition for a long period of time, and to provide a method for stabilizing an emulsion of soybean protein. SOLUTION: This liquid enteral nutrition composition comprises &gt;=40 wt.% based on total protein of soybean protein. Especially the liquid enteral nutrition composition contains a necessary and sufficient amount of essential trace elements such as zinc, copper, manganese, selenium, chromium, molybdenum, etc., soybean oligosaccharide, etc., being useful components in soybean by using a soybean milk as a soybean protein source. This method for stabilizing an emulsion of soybean protein comprises adding &gt;=5 mass pts. of a phosphate or a citrate to 100 mass pts. of soybean protein.
309,012. Weissbein, S. Jan. 2. 1928. Salves; emulsions, making.-A process for the manufacture of curative creams for external use by saponifying fats or fatty acids with alkali, insufficient for neutralisation, and in the presence of colloid protectors such as glycerine and a saponin and while saponification is proceeding, introducing into the mixture with stirring a concentrated solution of a healing salt together with a saponin until a cream-like mass is obtained. In an example 54 gms. of fat (or fatty acid) are partially saponified with 8 gms. KOH, 6 gms. of water, 10 ccs. of methyl or ethyl alcohol, and 0.01 gm. of, saponin on a water bath. Shortly before the end of the reaction there is stirred into the hot reaction mixture a heated solution of 40 gms. of &#34; Oeynhausen &#34; salt in 80 gms. water, admixed with 0.01 gm. of saponin and 10 gms. of glycerine. On stirring a creamy mass results which is spread out to cool. The &#34; Osenhausen &#34; salt is a mixture of sodium, potassium, and magnesium chlorides and sulphates, the sodium and chlorine ions predominating, together with small quantities of lithium, calcium, manganese, aluminium, iron phosphates. and arsenates. Common salt may be used instead of this mixture of salts.
Disclosed herein are unique systems and methods for remotely located physician specialists to diagnose and treat patients in a non-acute care facility having symptoms typically indicating a need for transfer to an acute care facility. The disclosed principles minimize the transfer of patients from a non-acute care facility to an acute care facility when not needed. The disclosed principles provide for the use of telemedicine units by geographically remote physician specialists to diagnose and treat patients in a non-acute care facility. If the physician specialist determines via the telemedicine unit that transfer of the patient to higher level of facility is needed, then the patient is transferred. If the physician specialist determines that the patient&#39;s new, elevated condition may be treated in the current, lower level facility, the physician specialist can prescribe a treatment for the current facility&#39;s staff to implement, even under the supervision of the physician specialist if it is needed. This unique approach is possible by providing an advanced telemedicine unit for use by the physician specialist that is geographically remote from the patient and his current lower level of care facility. Accordingly, the disclosed telemedicine program uses remote physicians having a higher level of skill or specialty to diagnose and treat patients currently located in a lower level healthcare facility than that type of specialty physician is typically found.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an impregnation sheet for uniformly applying a thixotropic base agent to a treating surface.  &lt;P&gt;SOLUTION: The impregnation sheet has a 1st fiber layer 1 containing non-shrinkable fibers and a 2nd fiber layer 2 placed adjacent to the 1st layer and containing heat-shrunk fibers. Both fiber layers are partly integrated in thickness direction through a number of junction parts 3 and the 1st fiber layer 1 is protruded between the junction parts 3 by the heat-shrinkage of the 2nd fiber layer 2 to form a number of protrusions 4. A thixotropic agent is impregnated in the obtained steric nonwoven fabric 10. The sheet is used by contacting the 1st fiber layer 1 with the treating surface.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for diagnosing Alzheimer&#39;s disease before significant neuronal loss arises, and a curative treatment for controlling the development of the disease.  &lt;P&gt;SOLUTION: This invention intends to provide a biomarker based on a protein useful for certifying clinical condition of the patient with Alzheimer&#39;s disease and a combination of the biomarker. Specifically, this invented biomarker is of service to classify a test sample as Alzheimer&#39;s dementia, non-Alzheimer&#39;s dementia, or normal. This biomarker can be detected by SELDI mass spectrometry. Further this invention provides suitable healthcare intervention and a method for measuring treatment response. This invented specific biomarker may also be preferable for use as a radiolabeled ligand in any noninvasive imaging technique such as positron-emission tomography (PET) and the like.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
Pharmaceutical compsns. contain as essential active component a strain of a &#39;micropredator&#39; microbe (I) capable of destroying other microbes by its direct action on them. (I) is pref. of the genus Bdellovibrio, specifically B.bacteriovorus CBS 648.73 or 649.73 or its natural or artificial mutants. Used to treat infections and, non-medically, as additives for animal feeds; for treating sewage effluent; purifying water; cleaning soiled linen, Treating soils, walls or hospital waste. Compsns. can be given orally, topically, parenterally etc. depending on the site of infection.
The present invention relates to a pill for treating collateral and gynecological diseases, and belongs to the field of traditional Chinese medicines. The pill is prepared from raw materials: 10 to 50 portions of cantharis, 10 to 50 portions of dragon&#39;s blood, 10 to 50 portions of croton, 10 to 50 portions of catechu, 10 to 50 portions of myrrh and 10 to 50 portions of frankincense. The crotons are peeled, the oil is removed, and the residues are taken. The heads, the feet and the wings of cantharides are removed. The six kinds of crude drugs are ground into fine powder by the weight proportion, and honey is added to be fine powder to be rolled into pills. The pills are put in a sterile gauze bag with a pull rope to be spare. The pill has the advantage that the pill for treating collateral and gynecological diseases covers the whole body, the channel system of the whole body is thoroughly improved from head to foot, and wind cold, rheumatism, neuralgia and gynecology inflammation caused by various reasons can be effectively treated; the cure rate for treating patients with uterine cold infertility can achieve 100%; the effective rate for treating patients with wind cold damp impediment periphery arthralgia can achieve 99.9%; the treatment course is short; the cost is low.
PROBLEM TO BE SOLVED: To provide a patch material which well holds a liquid component in a tacky adhesive layer and has a low stimulus property. SOLUTION: This patch material is constituted by forming the tacky adhesive layer on one surface of a base. The tacky adhesive layer contains an acrylate polymer having a weight average mol. wt. of &gt;=2500000 and a liquid plasticizer compatible with the polymer. More adequately, the acrylate polymer is a copolymer copolymerized by using an alkyl (meth)acrylate as an essential component.
In alternative embodiments, provided are methods for treating, ameliorating, decreasing the chances of having any adverse effects from, decreasing the severity of adverse effects from, or preventing an infection, or boosting or enhancing natural immunity acquired by an infected individual, by administration of: an inactivated infectious causative agent of the infection, or an antibiotic and/or an anti-viral drugs and a vaccine directed to a causative agent of the infection and/or an attenuated and/or a live, viable or infectious causative agent of the infection. In alternative embodiments, the infection is bacterial or viral. In alternative embodiments, the viral infection is a coronavirus infection such a Covid-19 infection. In alternative embodiments, methods as provide herein prevent or decrease the prevalence or severity of &#34;vaccine breakthrough infections&#34; after vaccination, where external mutants of COVID-19 infect patients in spite of the fact that they have undergone immunization, for example, to prevent a mutant or variant COVID-19 infection. In alternative embodiments, an antiviral combination administered in coordination with a vaccine comprises PF-07321332 or PAXLOVID? and/or ritonavir, or ivermectin, doxycycline and a zinc or a zinc salt. In alternative embodiments, methods as provided herein are used to prevent in vivo mutations of such mutant infectious agent to enhance the efficacy of an administered vaccination; in other words, methods as provided herein are used to prevent in vivo replication of an acquired viral mutant or variant infectious agent, and thus also prevents ongoing mutations of the viral infectious agent because using the combination antiviral co-therapy where there is no replication of infectious agent and so there is no possible further mutation of the infectious agent.
A method is disclosed for individually tailoring the administration of dietary components such as supplements. In the method, whole blood of a mammal is exposed to a dietary component. The level of a marker mRNA linked to a disease state is measured in leukocytes after exposure to the dietary component, and in some cases after further stimulation of the exposed blood cells. By comparing the mRNA level after exposure with the value found in unexposed blood cells, it is possible to determine what the effect of the dietary component will be in the mammal. By screening blood of the mammal against a number of possible dietary components, it is possible to develop an optimized set of dietary components tailored to the specific mammal to treat or prevent a disease state. ® KIPO &amp; WIPO 2008
1407720 Carrier bound macromolecular compounds BOEHRINGER MANNHEIM GmbH 4 Dec 1973 [8 Dec 1972] 56025/73 Headings C3H and C3P Carrier bound macromolecular compounds (e.g. protein, nucleic acid, peptide, porphyrin, haemin, phosphatide, cerebroside, ganglyoside or glycoside, e.g. enzymes, antibodies or hormones) covalently bound on to the surface of a polymer body which permeates a molecular sieve body are obtained by reacting a macromolecular compound A with a compound B which contains at least one function capable of coupling with the macromolecular compound A and at least one further function capable of polymerization, whereafter there is added a molecular sieve material in wholly or partially unswollen state, the degree of cross-linking of which excludes the macromolecular compound A, and the polymerizable group of the coupled product AB is then polymerized in the molecular sieve material. The compound B may comprise a group which alkylates or acylates the macromolecular compound and as the polymerizable group a carbon-carbon or carbon-oxygen double bond. The coupling function may be an oxirane, ethyleneimine, halide, acid halide, azide or anhydride group and may, for example have the formula in which R 1  is a mono- or polyunsaturated aliphatic hydrocarbon radical optionally containing one oxo group adjacent to a double bond and R 2  is a hydrogen atom or a lower alkyl radical. Compound B is preferably acryloyl chloride, allyl bromide, maleic anhydride, maleic acid azide, 1-allyloxy-3-(N-ethyleneimine) - propan - 2 - ol, acrylic acid 2,3 - epoxypropyl ester, but-2,3-ene oxide, methacrylic acid-2,3-epoxypropyl ester, maleic acid 2,3- epoxypropyl monoester, fumaric acid epoxy-(2, 3-epoxypropyl ester), fumaric acid epoxy-(2,3- epoxypropyl diester), fumaric acid epoxy-(2,3- epoxypropyl diester) or 1-allyloxy-2,3-epoxybutane. The molecular sieve material is advantageously cross-linked dextran, cross-linked polyacrylamide or cross-linked agar. In the examples glucose oxidase is coupled to an acrylamide/N,N&lt;SP&gt;1&lt;/SP&gt;-methylene bis-acrylamide copolymer obtained by polymerization thereof using ammonium peroxydisulphate or to a cyanogen bromide activated cross-linked dextran gel. Poly A is attached to a polyacrylamide/N,N&lt;SP&gt;1&lt;/SP&gt;- methylene bis-acrylamide copolymer.
Living tubercle bacilli for use in therapeutics and for use in the manufacture of therapeutic preparations are obtained in morphologically, chemically, and physiologically changed state by repeated cultivation on synthetic media containing lipoid-splitting enzymes.  Other enzymes may also be added to the media.  Suitable enzyme preparations may be obtained from pancreas, blood, liver, or lungs of animals, from seeds such as castor beans, soya beans or croton seeds, or from the amanita species of fungus.  The bacilli treated may be of the human, bovine, or bird types.  According to an example tubercle bacilli are inoculated in Lockemann&#39;s solution, without glycerine, to which a glycerine extract of pancreas has been added and are repeatedly sub-cultivated on this medium.  According to another example the medium consists of Lockemann&#39;s solution to which lipase solution has been added.
148,203. Strubell, A. April 2, 1914, [Convention date]. Vaccines and immunizing and like serums.- Relates to a process for obtaining cow&#39;s milk having the property of conferring immunity to tuberculosis. A cow is treated for a period of months prior to and after calving with relatively large and increasing doses of a vaccine containing killed human fatty tubercle bacilli or, preferably, disintegrated or opened-up preparations thereof containing the whole of the partial antigens, both soluble and insoluble. The bacilli employed are preferably cultivated in the manner described in Specification 148,202. The milk of such an animal is stated to contain free partial anti-bodies, and to confer immunity on a person consuming it. Tables are given showing the doses of vaccine employed and the results of tests of the blood serum and milk serum of the cows and of the blood serum and reactions of the calf. The Specification describes also a known process for obtaining an immunizing-milk in which the cow is treated with a vaccine containing only the water-soluble partial antigens of the disintegrated bacilli and the toxin thereof. The method of obtaining such vaccine from the bacilli and from the culture medium by cold processes and by processes involving heating are described in detail, and a table of the doses employed is given. The Specification as open to inspection under Sect. 91 of the Act refers also to a still more prolonged treatment of the animal whereby milk containing free antigens in addition to the antibodies is stated to be obtained and to be capable of conferring active immunity on the consumer. This subject-matter does not occur in the Specification as accepted.
The present invention relates to pyrazole fused-ring derivatives, their preparation methods, and use thereof in medicine. In particular, the present invention relates to a novel derivative 5 represented by formula (I), and a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the same and a method for preparing the same. The present invention also relates to use of the derivatives and the pharmaceutically acceptable salt thereof or the pharmaceutical composition comprising the same in the preparation of therapeutic agents, in particular Bruton tyrosine kinase inhibitors, and preparing a medicament for treating and/or 10 preventing tumors and inflammatory associated diseases. The substituents on formula (I) are defined same as in the specification. B i- `B- Li ., P -----L , A3 R 4 N, 1 A v \ A .1 \&#34;-A2 - --L2 - - ^ . R2 (I) 15
PURPOSE: Provided is an acetylcholinesterase (AChE) inhibiting crude drug composition which inhibits the AChE, and is effectively used in preventing and treating various diseases due to the concentration reduction of the in vivo acetylcholine, such as senile dementia like Alzheimer&#39;s disease, myasthenia gravis, asthenia of gastrointestinal tract and urinary bladder smooth muscle, and glaucoma. CONSTITUTION: The AChE inhibiting crude drug composition comprises an essential oil extracted from a mixture of Mentha arvensis var. piperascens Mak., Cinnamomum cassia Blume, Amomum cardamomum L., Cnidium officinale Makino or Angelica genuflexa Nutt, and Agastache rugosa Fisch. et Mey. or Pogostemon cablin Bent., or a mixture of essential oils from the respective herbs. A medicine, a food or an aroma is made using the composition.
PROBLEM TO BE SOLVED: To obtain scarcely water-soluble composition having a peptide/protein medicine and EDTA, excellent in long-lasting releasability and chemical stability, and useful as a pharmaceutical agent. SOLUTION: This scarcely water-soluble composition is obtained by dissolving a peptide or protein agent (e.g. salmon calcitonin) having at least one amino acid residual group selected from Lys and Arg, and EDTA (e.g. disodium edetate) in an aqueous solvent and subsequently allowing the obtained aqueous solution to stand until the composition is obtained. The composition contains 2.5-5mg of EDTA based on 5-10mg of the peptide or protein agent, and &gt;=1.0mg to &lt;= the saturating amount of the peptide or protein agent and &gt;=5mg of EDTA based on 1ml of the aqueous solvent. The composition can be formulated into an injection, a nasal drug, a transpulmonary drug or an oral drug, and a dose is 0.1×g to 50mg in terms of a calcitonin e.g. when the calcitonin is used as the peptide or protein agent.
&lt;P&gt;PROBLEM TO BE SOLVED: To identify an oxidation reduction substance newly restored as H&lt;SB&gt;n&lt;/SB&gt;O by decomposing water (H&lt;SB&gt;2&lt;/SB&gt;O) into hydrogen atoms and oxygen atoms by oxidation reduction, and to provide a method for utilizing the substance.  &lt;P&gt;SOLUTION: An aqueous solution in which dolomite hydroxide and alumina are mixed remains as the newly restored oxidation reduction substance in a reaction chamber. The hydrogen atoms dissipate as molecules H&lt;SB&gt;2&lt;/SB&gt;, and the hydrogen atoms which remain as H&lt;SB&gt;n&lt;/SB&gt;O, and free electrons emitting from the alumina serve as the drive force for reduction power. The mixture aqueous solution is named as HRM (hydrogen reduction matter), and after the solution is left to stand for about 24 hours, the solid portion is precipitated. The supernatant portion is named as HRW (hydrogen reduction water), and both of HRM and HRW are used as oxidation reduction materials.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
A system and method generates customized health-related messages for one or more health plan members. The customized messages may include customized information relevant to each recipient member based on available member data, and provide the members with education, resources, knowledge and/or guidance on a member&#39;s accounts, benefits, health-related conditions and wellness potentially needed to make better-informed healthcare decisions. Messages may be provided to members and/or healthcare personnel involved in the care of plan members. To provide customized messages relating to one or more health plan members, member data is compiled to identify one or more outcomes related to the member data for each member. The outcomes are risk-stratified, and message data is generated based on the risk-stratified outcomes. The message data is configured based on the member&#39;s plan benefits, and customized messages including the configured message data are provided to the respective members and/or healthcare personnel.
PURPOSE:To provide a carcinostatic agent containing 5,7,4&#39;-trihydroxyisoflavone as an active component and having tumor cell proliferation inhibiting activity and DNA-synthesis inhibiting activity. CONSTITUTION:The objective agent contains 5,7,4&#39;-trihydroxyisoflavone (general name: genistein) as an active component. Genistein is a compound separated from a certain kind of clover (Trifolium subterraneum L.) and is known to have week estrogen activity. It has been found newly that the compound is effective to inhibit the proliferation of tumor cell, the synthesis of DNA and the activity of tyrosine-specific phosphorylase. Coupled with the low acute toxicity, the compound is useful as a carcinostatic agent for the remedy of human and animal cancer, the remedy for diseases caused by the metastasis of cancer and the prevention of relapse of cancer. It is applied at a rate of usually 200-1,000mg daily in 1-4 divided doses.
FIELD: medicine, veterinary science. SUBSTANCE: protective antigen is characterized by sugars&#39; content up to 60%, proteins up to 20%, nucleotides up to 5%, it has molecular weight below 30 kDa and maximum absorption within 250-265 nm wave lengths. Antigen is obtained during cultivation of Brucella in nutritive medium at 5.5- 7.0 pH. The former is isolated out of liquid fraction of culture liquid presubjected to either acidic or alkaline hydrolysis and purified due to ultrafiltration or liquid chromatography. The method provides to obtain antigen capable to provoke latent forms of brucellosis. EFFECT: higher efficiency. 3 cl, 12 ex, 2 tbl
Water can either naturally contain or can be made to contain an added level of an environmental force called KELEA, an abbreviation for Kinetic Energy Limiting Electrostatic Attraction. Placing KELEA activated water directly onto the area of skin with vitiligo leads to re-pigmentation of the affected area of skin. The therapy is attributed to enhancing the body&#39;s alternative cellular energy (ACE) pathway. This pathway has an anti-inflammatory effect and also a regenerative effect referred to as REACH, an abbreviation for Regenerative Energy Assisted Clinical Healing. The restoring of melanocyte in patients with vitiligo will likely apply to other illnesses in which there is melanocyte degeneration, including Parkinson&#39;s disease. Enhancing the ACE pathway using KELEA-activated water is also applicable to other illnesses classified as being autoimmune. The KELEA activated water can also be used in wearable waterceutical pouches.